Current and future therapies for hepatitis C virus infection. - Test2 - elhamkhani - TriplyDB

Current and future therapies for hepatitis C virus infection.

Current and future therapies for hepatitis C virus infection.

http://www.wikidata.org/entity/Q34036762

about

Treatment for hepatitis C virus-associated cryoglobulinaemic vasculitis Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection Hepatitis C virus-associated B-cell non-Hodgkin's lymphomas: what do we know?Infectious Aetiology of Marginal Zone Lymphoma and Role of Anti-Infective Therapy Entry inhibitors: New advances in HCV treatment New approaches in the treatment of hepatitis C Chronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.Chronic hepatitis C: This and the new era of treatment Interferon Response in Hepatitis C Virus (HCV) Infection: Lessons from Cell Culture Systems of HCV Infection Autophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseases (-)-Epigallocatechin-3-Gallate Enhances Hepatitis C Virus Double-Stranded RNA Intermediates-Triggered Innate Immune Responses in Hepatocytes.(4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry Enhancing our understanding of current therapies for hepatitis C virus (HCV)Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance Genomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practice Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.Hepatitis C virus infection in China: an emerging public health issue.Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients.IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin.The hepatitis C cascade of care: identifying priorities to improve clinical outcomes Therapeutic Potential of Spirooxindoles as Antiviral Agents Sofosbuvir.IFN-λ4 potently blocks IFN-α signalling by ISG15 and USP18 in hepatitis C virus infection.Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle Hepatitis C virus screening practices and seropositivity among US veterans born during 1945 - 1965 Trace amounts of sporadically reappearing HCV RNA can cause infection Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423 Hepatitis C virus entry is impaired by claudin-1 downregulation in diacylglycerol acyltransferase-1-deficient cells.Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey.New pyrazolobenzothiazine derivatives as hepatitis C virus NS5B polymerase palm site I inhibitors.Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection.IFN-λ Inhibits MiR-122 Transcription through a Stat3-HNF4α Inflammatory Feedback Loop in an IFN-α Resistant HCV Cell Culture System.Sustained Virologic Response for Chronic Hepatitis C Infection after 27 Days of Treatment with Sofosbuvir and Ribavirin.Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline.Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C.Prevalence and correlates of hepatitis C virus infection among inmates at two New York State correctional facilities.

P2860

Q24188154-E4B9FAA1-18E1-470A-AE30-915AB3DDFFD1 Q26746563-2BB03E92-3D57-4CBB-9648-F0C6C08F7CB2 Q26750997-7B66BD55-19AC-460A-AF21-67B12750E172 Q26770344-9ACB2B4D-C0EC-42CA-9737-67C60F1A3B20 Q26770817-C06F0C5E-65E7-4441-8F78-D1D51E674E05 Q26773271-9456C3CD-31AE-466C-8743-2E53125C78A8 Q26773585-F82F2A62-A857-4CE7-8E15-45683D890F3B Q26775011-D0711E09-F938-478A-93DC-5911531E173B Q26784252-77FF6989-FEAD-48CA-B6B0-D6B945A925F3 Q26992256-7959E233-E082-4CB1-BF11-6755340A9F30 Q27346473-3A221414-D5B3-4E36-811D-574C1C5F21F0 Q27468939-228BDE63-C08C-4FCE-8FB0-FF1783B18FE4 Q28085718-820E61FC-1FC4-46FE-9B09-507DAFD69122 Q28538891-C904D119-F0F1-4DC2-9459-D13ADDD71720 Q28540848-19FD7626-1F91-4537-B333-664433BDB431 Q28543022-596A3D9C-3BEC-48FF-B3FD-0576346D9D53 Q30209037-7EF2A782-C0CC-4D04-BC24-3538BE8FD879 Q30365797-DAFEA41E-0349-42FB-ACE8-C2F830A60C3B Q30430083-400EB3A9-15F8-4A5D-8163-185F55B72DE2 Q33596086-415D2429-688A-43C5-8906-C53F37826404 Q33632459-FEABF604-D746-48AD-9E8D-B6C23244395B Q33637160-1CD83F0A-2598-4AE0-B3BE-7BF0AB271C31 Q33774724-4BD26316-987E-413F-856F-7A4B7E0AF201 Q33812521-4A37F730-EBF2-4618-9CCF-BF21989589FE Q33893794-2FC70451-3996-424C-851E-69BE1FF24317 Q33929521-8F75B6E7-2BFF-4F3B-B76A-73734E16F92C Q33944273-34D47127-D853-4FE6-B9E7-185D9487A779 Q33944295-545F9348-B751-4998-ADE8-9C17D92DFA6C Q34036824-B0E433D9-71C0-4C54-9CDE-72D9E7E73862 Q34047477-4688FD33-53B1-47D8-85F6-AB1BE38059B8 Q34059207-2A1703D6-1F9C-4F51-8BDE-E677B682D7C3 Q34260638-6EDC325D-C322-4C0A-8C03-1B8EFE8D9741 Q34372464-48C1385C-AEA6-4DDF-9792-34EF33518E38 Q34470890-002DBDD9-B6EA-482B-A50B-356188567791 Q34504772-C57B6680-A220-4001-937D-F68A9C4BFAFA Q34520844-BEE00B05-2FB5-446B-9EF5-CCA49ECCDAF8 Q34522481-D6E57B5B-DBFE-4936-AD18-46241470BE01 Q34524584-86662CB0-28FB-4BBE-B69B-BDA09C470037 Q34586112-097F976B-2836-404B-9AB7-714C46F0CBD6 Q34620876-59B75433-8C2C-40D7-83EC-527382EE90B0

P2860

Current and future therapies for hepatitis C virus infection.

http://www.wikidata.org/entity/Q34036762

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Current and future therapies for hepatitis C virus infection.

@ast

Current and future therapies for hepatitis C virus infection.

@en

Current and future therapies for hepatitis C virus infection.

@nl

type

label

Current and future therapies for hepatitis C virus infection.

@ast

Current and future therapies for hepatitis C virus infection.

@en

Current and future therapies for hepatitis C virus infection.

@nl

prefLabel

Current and future therapies for hepatitis C virus infection.

@ast

Current and future therapies for hepatitis C virus infection.

@en

Current and future therapies for hepatitis C virus infection.

@nl

P1433

Q34036762-9B399CED-3160-4E75-BBA6-4B405E5B1850

P1476

Q34036762-39E0C6EB-5E81-48E4-8E6B-898F886AB551

P2093

Q34036762-00A3E884-F7C6-44F9-B043-20911711FA47

Q34036762-2D7ABC00-3E27-465E-9060-1E536F6C7058

P2860

Q34036762-01B62D2A-548D-4999-A8A3-65D64B079A27

Q34036762-0A1C7C84-0998-461A-9633-4657EDDDAD35

Q34036762-0AF0BF45-1289-4016-B039-ADDFEF373296

Q34036762-0C212A43-85C6-4A12-8597-0BD651148795

Q34036762-0D49B29E-2EF1-497E-989E-5B8E6F06BEC6

Q34036762-0FE2A29F-4897-4255-953C-1D917FBE98E6

Q34036762-19054C75-93F8-4A99-8030-2083FCB5E0FA

Q34036762-192ADC2B-6FB6-470D-A905-50A2BAD6DA23

Q34036762-1CF6EAD1-95E3-4349-9E0E-E88FF918423C

Q34036762-1D89B888-C901-4739-AD8E-6219AD7F0C65

P304

Q34036762-482954C7-A557-405F-B789-7C7B26E4A5ED

P31

Q34036762-82D98CA9-0378-4F44-BC45-C5760B665692

P356

Q34036762-E4DC7C75-4591-42D9-9B97-964500404F05

P407

Q34036762-6F14389E-A741-43B6-858B-4DA12186CC00

P433

Q34036762-AB403E6E-CDF8-49FE-B886-661A4859CEEB

P478

Q34036762-BA283920-C456-42F4-ACF5-2CF44BD9DFB3

P577

Q34036762-4EA0F456-D2FD-4CEF-BCE3-233620076709

P5875

Q34036762-D4E981B0-62E8-4860-8908-934B2F5444F9

P698

Q34036762-2EFD9A16-04EE-49B4-AD44-F4BD2AE04279

P932

Q34036762-45E58B87-5ABE-485D-93CE-F9EB48187C67

P356

P1433

The New England Journal of Medicine

P1476

Current and future therapies for hepatitis C virus infection.

@en

P2093

Marc G Ghany

http://www.w3.org/2001/XMLSchema#string

T Jake Liang

http://www.w3.org/2001/XMLSchema#string

P2860

Boceprevir for previously treated chronic HCV genotype 1 infection

Review and management of drug interactions with boceprevir and telaprevir

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles

The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives

Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence

Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA

Treatment of HCV infection by targeting microRNA

Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

P304

1907-1917

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMRA1213651

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

368

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236910446

http://www.w3.org/2001/XMLSchema#string

P698

23675659

http://www.w3.org/2001/XMLSchema#string

P932

3893124

http://www.w3.org/2001/XMLSchema#string